Osteoporosis Drugs Market Size, Competitive Landscape and Market Forecast - 2029
Global Osteoporosis Drugs Market is Segmented By Drug Class(Bisphosphonates, RANK Ligand Inhibitors, Selective Estrogen Receptor Modulators, Parathyroid Hormone Analog, Strontium, Calcitonin, Anti-Sclerostin, and Cathepsin K Inhibitor) By Product Type(Branded and Generics), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy and Other), and By Region (North America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
Market- Overview
The Global "Osteoporosis Drugs Market" size was valued US$ XX million in 2019 and is estimated to reach US$ XX million by 2028, growing at a CAGR of 4.30% during the forecast period (2022-2029).
Osteoporosis is a skeletal disorder characterized by the gradual weakening of the bones, which occurs due to hormonal fluctuations, vitamin deficiency, or aging. It leads to excessive loss of bone mass, bone fragility, increased risk of fractures. The condition can lead to severe fractures, which can harm patient health. Therefore, the state requires treatment, which includes osteoporosis drugs.
Market Dynamics
The global osteoporosis drugs market growth is driven by the rise in the prevalence of osteoporosis. Furthermore, other factors that drive the development of the osteoporosis drugs market are a surge in the geriatric population across the globe and a rise in the adoption of sedentary lifestyles worldwide.
The growing investments in research and development by biotechnology and pharmaceutical companies will drive market growth.
The growing investments in research and development by biotechnology and pharmaceutical companies drive market growth in the forecast period. For instance, in October 2020, the Italian pharmaceutical regulatory agency granted human clinical trials on raloxifene, a generic osteoporosis drug that researchers hope may also help reduce COVID-19 symptoms and make patients less infectious. Thus, positive results from clinical trials may lead to new treatment options, thereby boosting the market growth in the future.
Higher incidence & prevalence of osteoporosis across the world is the primary driver for the growth of the global osteoporosis drugs market. According to the National Osteoporosis Foundation, in 2018, an estimated 10 million people had osteoporosis, and another 44 million had a low bone density, placing them at increased risk in the United States. The rising geriatric population globally, who are prone to low bone density, is another main factor for the market's growth. For instance, as per the data published by the International Osteoporosis Foundation in 2020, 1 in 5 men and 1 in 3 women over age 50 years may experience osteoporosis fractures in their remaining lifetimes across the globe.
The development of novel approaches for the treatment of osteoporosis by new drugs and increase in awareness among people for the early diagnosis & treatment are also significant factors for the growth of this market.
A low rate of treatment with bone-directed medications is likely to hamper the market growth.
However, treatment rates with osteoporosis, or bone loss, medicines dropped dramatically over the past decade from 15 percent to 8 percent, a new analysis of an extensive nationwide private insurance database found. Less than one in 10 commercially insured patients in the United States who broke a hip, a major complication of osteoporosis, receive any osteoporosis medical treatment within two calendar quarters of their fracture, according to a study whose results will be presented at ENDO 2021, the Endocrine Society's annual meeting. These factors hamper the growth of the market in the forecast period.
COVID-19 Impact Analysis
COVID-19 is disrupting and delaying the treatment of many patients with osteoporosis; hence, the American Society for Bone and Mineral Research (ASBMR) set up a steering committee of bone specialists to manage the treatment of targeted disorders pandemic. For instance, in April 2020, a paper on the evidence behind the recommendations was published in the American Society for Bone and Mineral Research (ASBMR) official journal, the Journal of Bone and Mineral Research. The guidelines recommended that the patients continue osteoporosis medications when possible to do so safely and that initiation of new oral bisphosphonate therapy can be done remotely and should not be delayed in patients at high risk for fracture. Thus, COVID-19 is expected to impact regional market growth profoundly.
Several research studies suggested that apart from drugs used for anti-viral treatments, other drugs such as osteoporosis drugs may also prove helpful in COVID-19 treatment, which may boost the market. For instance, as per the study published in 2020, "Common osteoporosis treatment may help reduce the incidence of COVID-19", reported that treatments such as denosumab, zoledronate, and calcium, used for the treatment of osteoporosis, could protect against COVID-19 as well.
Segment Analysis
RANK Ligand Inhibitors segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
RANK ligand (RANKL) inhibitors are used to manage osteoporosis in patients at high risk for bone fractures. The high growth possibility achieved results from positive patient results associated with rank ligand inhibitors. The positive patient outcomes can be credited to significant improvements in bone metabolism. Rank ligand inhibitors can also be utilized with other drugs to impart a synergistic effect in the overall treatment regime. The factor mentioned above is also anticipated to be one of the critical factors accountable for presenting profitable opportunities. Other advantages of rank ligand inhibitors are reduced cell bone turnover and increased bone mineral density, thereby implicating high demand. Because RANKL is expressed in lymphocytes, special attention was given to evaluating immune function. No clinical or laboratory evidence of an adverse effect on the immune system was noted. Finally, another critical function of the RANK/RANKL/OPG pathway is the regulation of glucose homeostasis. Blocking RANK activity in mouse liver protects against diet-induced glucose intolerance.
The RANK ligand may be effective as prophylaxis for COVID-19. As per the study conducted at the Hospital Del Mar, a general hospital in Spain, in 2020, denosumab targets the RANK/RANKL system, which is involved in maintaining balance in the skeletal system. It is involved in lymph node development T cell activation and affects the immune system. Inhibition of this system reduces pro-inflammatory cytokines in the body and helps control inflammation, which is one of the major causes of life-threatening COVID-19. Thus, owing to the broad Product Types of RANKL, the segment is likely to grow at a faster pace.
Geographical Analysis
North America region holds the largest market share of the global osteoporosis drugs market
North America is expected to dominate the overall osteoporosis drugs market in the forecast period. The market growth is due to the factors such as the presence of key players, the high prevalence of osteoporosis patients in the region, established healthcare infrastructure, and the availability of branded drugs.
In the North American region, the United States holds the largest market share due to an increasing geriatric population, a growing patient pool in the country, and several collaborative efforts commenced by significant companies to enhance their abilities and guarantee high medical standards. For instance, as per the data published by the National Osteoporosis Foundation (NOF), as of 2020, more than 10 million people in the United States had osteoporosis, which is most common in women who have gone through menopause. Thus, an upsurge in incidence resulting from menopause in women is anticipated to be a critical growth contributing factor to the regional osteoporosis drug market.
The increasing demand is also predicted to result from collaborative research initiatives implemented by the primary healthcare organizations and companies and new product development consistently striving to improve treatment alternatives in the current market space. For instance, in 2019, Amgen announced that the US Food and Drug Administration approved its Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). This may open up the growth horizon to the regional market.
Competitive Landscape
The osteoporosis drugs market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market include Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline PLC, Novartis International AG, and Actavis PLC. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the osteoporosis drugs market globally. For instance, in June 2020, Alvogen launched Teriparatide Injection in the United States. Teriparatide Injection (also referred to as PF708 and Bonsity) is a prescription medicine approved for several uses, including in postmenopausal women with osteoporosis who are at high risk of having bone fractures.
Pfizer Inc.
Overview:
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing, marketing, sales, and distributing biopharmaceutical products. Its global portfolio includes medicines and vaccines.
Product Portfolio:
DUAVEE: DUAVEE is used after menopause for women with a uterus to reduce moderate-to-severe hot flashes and to help reduce the chances of developing osteoporosis.